Table 1.
The examples of successful CAR T therapy in liquid cancer and solid cancer.
| Targets | Disease | Outcomes | Product/Pre-Clinical Trail/Clinical Trails |
|---|---|---|---|
| CD19 | Acute lymphoma leukemia | Success in pre-clinical study | [36] |
| CD19 | Acute lymphoma leukemia | Success in pre-clinical study | [37] |
| CD19 | Relapsed/Refractory B cell precursor ALL | Success | Tisagenlecleucel/Kymariah |
| CD19 | Relapsed/Refractory large B cell lymphoma | Success | Axicabtagene ciloleucel/Kymariah |
| CD19 | Relapsed/Refractory follicular lymphoma (FL) | Success (May 2022, FDA-approved) | Axicabtagene ciloleucel/Kymariah |
| BCMA | Relapsed/Refractory multiple myeloma | Success (February 2022, FDA-approved) | Ciltacabtagene autoleucel/Carvykti |
| BCMA | Relapsed/Refractory multiple myeloma | Success (March 2021, FDA-approved) | Idecabtagenevicleucel/Abecma |
| CD19 | Relapsed/Refractory large B cell lymphoma | Success (February 2021, FDA-approved) | Lisocabtagene autoleucel/Breyanzi |
| CD19 | Relapsed/Refractory B cell lymphoma | Success (October 2017, FDA-approved) | Axicabtagene ciloleucel/Yescarta [162] |
| CD19 | Relapsed/Refractory follicular lymphoma (FL) | Success (March 2021, FDA-approved) | Axicabtagene ciloleucel/Yescarta |
| IL13R | Glioblastoma | Success in preclinical trials | [163] |
| Epidermal growth factor receptor variant III (EGFRvIII) | Recurrent Glioblastoma | Success in human patient | [164] |